237 related articles for article (PubMed ID: 21437145)
1. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence.
Murphy KR; Bender BG
J Asthma Allergy; 2009 Jul; 2():63-72. PubMed ID: 21437145
[TBL] [Abstract][Full Text] [Related]
2. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
3. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
Kuna P
Clin Drug Investig; 2010; 30(9):565-79. PubMed ID: 20593912
[TBL] [Abstract][Full Text] [Related]
4. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
Kew KM; Dias S; Cates CJ
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
[TBL] [Abstract][Full Text] [Related]
5. [Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
Korn S; Vogelmeier C; Buhl R
Med Klin (Munich); 2008 May; 103(5):299-310. PubMed ID: 18484216
[TBL] [Abstract][Full Text] [Related]
6. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management.
Singh D; Garcia G; Maneechotesuwan K; Daley-Yates P; Irusen E; Aggarwal B; Boucot I; Berend N
Adv Ther; 2022 May; 39(5):1895-1914. PubMed ID: 35284999
[TBL] [Abstract][Full Text] [Related]
7. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
Vogelmeier C; Naya I; Ekelund J
Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
[TBL] [Abstract][Full Text] [Related]
8. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.
Buhl R; Vogelmeier C
Curr Med Res Opin; 2007 Aug; 23(8):1867-78. PubMed ID: 17605896
[TBL] [Abstract][Full Text] [Related]
9. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.
Kew KM; Karner C; Mindus SM; Ferrara G
Cochrane Database Syst Rev; 2013 Dec; (12):CD009019. PubMed ID: 24343671
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy in asthma--fixed or variable dosing in different patients?
Lötvall J
Curr Med Res Opin; 2004 Nov; 20(11):1711-27. PubMed ID: 15537472
[TBL] [Abstract][Full Text] [Related]
11. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.
Cates CJ; Karner C
Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007313. PubMed ID: 23633340
[TBL] [Abstract][Full Text] [Related]
12. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
13. Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma.
Dissanayake S; Grothe B; Kaiser K
Respir Med; 2012 Dec; 106 Suppl 1():S20-8. PubMed ID: 23273163
[TBL] [Abstract][Full Text] [Related]
14. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study.
Aalbers R
Clin Drug Investig; 2010; 30(7):439-51. PubMed ID: 20528000
[TBL] [Abstract][Full Text] [Related]
15. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.
Bodzenta-Lukaszyk A; Dymek A; McAulay K; Mansikka H
BMC Pulm Med; 2011 May; 11():28. PubMed ID: 21605396
[TBL] [Abstract][Full Text] [Related]
16. Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention.
Aalbers R; Vogelmeier C; Kuna P
Respir Med; 2016 Feb; 111():1-7. PubMed ID: 26614594
[TBL] [Abstract][Full Text] [Related]
17. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
O'Shea O; Stovold E; Cates CJ
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD007694. PubMed ID: 33852162
[TBL] [Abstract][Full Text] [Related]
18. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
19. Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma.
Mehta N; Aggarwal B; Gogtay J; Abdool-Gaffar S
Expert Opin Drug Deliv; 2015 Jun; 12(6):963-75. PubMed ID: 25429610
[TBL] [Abstract][Full Text] [Related]
20. Comparing the efficacy and safety of formoterol/budesonide pMDI versus its mono-components and other LABA/ICS in patients with asthma.
Mukhopadhyay A; Waked M; Gogtay J; Gaur V
Respir Med; 2020; 170():106055. PubMed ID: 32843176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
